GAM Holding AG Has $6.13 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

GAM Holding AG raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 42.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,320 shares of the medical research company's stock after acquiring an additional 3,695 shares during the quarter. GAM Holding AG's holdings in Thermo Fisher Scientific were worth $6,130,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Stonegate Investment Group LLC increased its stake in Thermo Fisher Scientific by 6.5% in the 1st quarter. Stonegate Investment Group LLC now owns 7,231 shares of the medical research company's stock valued at $3,598,000 after buying an additional 443 shares during the period. Worth Financial Advisory Group LLC increased its stake in shares of Thermo Fisher Scientific by 283.5% in the first quarter. Worth Financial Advisory Group LLC now owns 1,603 shares of the medical research company's stock worth $798,000 after acquiring an additional 1,185 shares during the last quarter. PFG Investments LLC raised its holdings in shares of Thermo Fisher Scientific by 4.0% during the first quarter. PFG Investments LLC now owns 2,222 shares of the medical research company's stock worth $1,106,000 after acquiring an additional 86 shares in the last quarter. Canoe Financial LP acquired a new stake in Thermo Fisher Scientific during the first quarter valued at $3,981,000. Finally, Rockline Wealth Management LLC grew its stake in Thermo Fisher Scientific by 9.2% in the first quarter. Rockline Wealth Management LLC now owns 1,669 shares of the medical research company's stock valued at $830,000 after purchasing an additional 140 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.33% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Argus reduced their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Scotiabank cut their price objective on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research report on Friday, April 25th. Citigroup decreased their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Robert W. Baird cut their price target on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Finally, Evercore ISI decreased their price objective on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $605.30.

Thermo Fisher Scientific Stock Performance

TMO traded up $4.75 during midday trading on Friday, reaching $397.31. The company's stock had a trading volume of 3,760,318 shares, compared to its average volume of 1,942,727. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88. The stock has a market cap of $149.98 billion, a P/E ratio of 23.30, a PEG ratio of 2.10 and a beta of 0.78. The company has a fifty day simple moving average of $412.62 and a 200 day simple moving average of $487.56. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. Thermo Fisher Scientific's quarterly revenue was up .2% on a year-over-year basis. During the same quarter last year, the company posted $5.11 earnings per share. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.